SCHEDULE: Rubric Capital Management Discloses Reduced Stake in Adaptive Biotechnologies
Beneficial Ownership Report
Rubric Capital Management LP and David Rosen have reported a 4.12% beneficial ownership stake in Adaptive Biotechnologies Corporation as of June 30, 2025, indicating a passive investment position.
Summary
- Rubric Capital Management LP and David Rosen collectively hold 6,256,847 shares of Adaptive Biotechnologies Corporation's common stock.
- This represents 4.12% of the company's outstanding common stock.
- The ownership is reported as of June 30, 2025.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing.
- The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine beneficial ownership report (Schedule 13G Amendment) disclosing a passive stake of 4.12% in Adaptive Biotechnologies. While the percentage is below the 5% threshold, suggesting a potential reduction from a previous filing, the document itself is purely factual and does not contain positive or negative operational or financial news.
Positives
- The investment by Rubric Capital Management, an institutional investor, could be seen as a vote of confidence in Adaptive Biotechnologies, although the percentage is below 5%.
- The filing confirms a passive investment strategy, not seeking to influence control.
Negatives
- The reported 4.12% ownership, being below the 5% threshold typically requiring a Schedule 13G filing, suggests a potential reduction in stake from a previous filing where Rubric Capital Management held 5% or more. This reduction by an institutional investor could be interpreted negatively by the market.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of institutional ownership in the biotechnology sector. It reflects an investment firm's position in Adaptive Biotechnologies, a company operating in the biotech space, but does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which may have decreased.
- Company Management: Awareness of a large, passive institutional holder's position.
Key Dates
| Date | Description |
|---|---|
| 2025-04-24 | Date as of which 151,916,722 shares of Common Stock were outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q. |
| 2025-05-01 | Date the Issuer's Quarterly Report on Form 10-Q for the period ended March 31, 2025, was filed with the SEC. |
| 2025-06-30 | Date of the event which requires the filing of this statement (reporting date for beneficial ownership). |
| 2025-07-09 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Adaptive Biotechnologies Corporation, Rubric Capital Management LP, David Rosen, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.